KenkoTech Futures

Stereotaxis has announced a collaboration with CardioFocus to develop a robotic PFA system for treating cardiac arrhythmias - integrating CardioFocus’ CE-marked Centauri PFA platform with Stereotaxis’ Magic robotic catheter. 🫀 The partnership represents an important step in the convergence of robotics and next-generation ablation technologies, aiming to enhance precision, safety, and procedural consistency in electrophysiology. With bench and preclinical testing complete and clinical trials imminent, this move positions both firms at the forefront of robotically assisted PFA - a fast-evolving field reshaping the treatment landscape for complex cardiac conditions. #MedTech #PFA #KenkoTechFutures

We're partnering with a fast-scaling HealthTech company transforming cardiovascular care through AI-powered imaging solutions. 🫀 They’re seeking a Technical Integration Specialist to lead the deployment and integration of advanced cardiovascular imaging systems into hospital IT environments - connecting cutting-edge AI with clinical workflows. If you’re passionate about bridging technology and healthcare - and want to play a hands-on role in bringing next-generation cardiovascular AI into hospitals across the US - we’d love to hear from you. Apply via the link or reach out to the KenkoTech Futures team today for more info. 🚀 https://lnkd.in/ejumP9FS #HealthTech #CardiacImaging #KenkoTechFuture

This Week’s Health & BioTech Funding Rounds 🚀 Health and BioTech investment is accelerating, driving advancements in precision medicine, AI diagnostics, and next-gen therapeutics. At KenkoTech Futures, we’re tracking the latest funding rounds shaping the future of healthcare. Here are this week’s key raises: FoxEyes Corporation (Seed) $540,000 Arcadia Medicine (Seed) $9.25M MediView XR, Inc. (Series A) $24M Hipp Health (Seed) $6.2M Self Fund Health (Seed) $1,399,998 HyperSpectral (Series A) $7M OraLiva, Inc. (Seed) $2M TORL Biotherapeutics LLC (Series C) $96M Affinia Therapeutics (Series C) $40M AeroRx Therapeutics (Series A) $21M Zingage (Seed) $12.5M ThirdLaw Molecular (Seed) $5.5M Lumen Bioscience (Series C) $30M Nilo Therapeutics (Series A) $101M TransCrypts (Seed) $15M Singletto (Series A) $10M CareLife (Seed) $331,640 Foundation Health (Series A) $20M Clanz Technologies Sensi.AI (Series C) $45M Expedition Therapeutics (Series A) $165M NVP Medical Group (Seed) $1.02M #KenkoTechFutures #HealthTech #BioTech #FundingRounds #Innovation #HealthcareTech #Startups

The Radiological Society of North America (RSNA)'s subsidiary, RSNA Ventures, has announced a strategic partnership with Rad AI, the U.S. software company pioneering generative AI for healthcare. 💡 This collaboration will integrate RSNA’s trusted, peer-reviewed medical knowledge directly into radiologists’ daily workflows through the Rad AI platform, helping clinicians manage increasing imaging volumes while maintaining quality of care. By surfacing case-based insights automatically, the partnership aims to streamline diagnosis, enhance decision-making, and reduce cognitive load - ensuring radiologists can focus more on interpretation and less on information retrieval. According to RSNA board member Dr. Adam Flanders, the partnership “leverages AI to optimise workflows to improve patient care,” while Rad AI’s co-founder Dr. Jeff Chang highlighted that connecting RSNA’s knowledge base with daily practice gives radiologists “an unprecedented advantage.” The first joint demonstration is set for RSNA 2025, showcasing how AI-driven knowledge integration can support radiologists in real time. ⚡️ #AIinHealthcare #Radiology #MedicalImaging

We’re partnering with an innovative biotechnology company at the forefront of genomics and multi-omics research, backed by ~$100M in Series B funding. 🧬 This is a rare opportunity to lead computational strategy, design next-generation bioinformatics tools, and help unlock biological insights that advance human health. If you’re passionate about biology, computation, and meaningful impact, this role offers a chance to shape the future of discovery. Apply today or get in touch to learn more. 🚀 https://lnkd.in/eZGAhXmk #KenkoTech #Bioinformatics #Genomics 

This Week’s Health & BioTech Funding Rounds 🚀 Health and BioTech investment is accelerating, driving advancements in precision medicine, AI diagnostics, and next-gen therapeutics. At KenkoTech Futures, we’re tracking the latest funding rounds shaping the future of healthcare. Here are this week’s key raises: Glyphic Biotechnologies (Series A) $38M Datawizz (Seed) $12.5M Neura Health (Series A) $11.4M Confido Health (Series A) $10M AiM Medical Robotics (Series A) $8.1M SureCo (Series A) $23M Crystalys Therapeutics (Series A) $205M Kilele Health Inc (Seed) $264,500 Mamaya Health (Series A) $3M Folia Health: The Home-Reported Outcomes Company (Series A) $10.5M Predicta Biosciences (Series A) $23.4M Ansa Biotechnologies, Inc. (Series B) $45,199,665 Hedge Health, Co. (Seed) $200,000 AccufyDx (Seed) $200,000 Koda Health (Series A) $7M Kihealth, Inc. (Seed) $5M OncoC4, Inc. (Series B) $50M DermaSensor, Inc. (Series B) $50M Midi Health (Series C) $50M Cartography Biosciences (Series B) $67M #KenkoTechFutures #HealthTech #BioTech #FundingRounds #Innovation #HealthcareTech #Startups

At the recent European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Aberdeen, researchers presented new findings on Hologic, Inc.’s AI-powered mammography technology. 💡 Key highlights: - AI scores on 3D mammography exams were linked with more aggressive tumor features, including higher-grade and node-positive cancers. - Early results suggest AI could match radiologists in detecting cancers, with higher sensitivity but lower specificity. - These findings highlight AI’s potential to act as a “second set of eyes,” improving accuracy, efficiency, and earlier detection - especially valuable given workforce shortages in breast screening. This research underscores the growing role of AI in advancing breast cancer detection and care, with the potential to transform both screening and diagnosis in the years ahead. #Mammography #Hologic #KenkotechFutures

Our client is a fast-growing AI medical imaging company with strong clinical traction and $50M in Series B funding. They’re building next-generation SaMD solutions that improve diagnostic accuracy and clinical efficiency. 🚀 They’re now seeking a Chief Medical Officer to shape clinical strategy and guide regulatory, medical affairs, and commercialization efforts as the company scales globally. 🌍 If you're an experienced clinical leader ready to shape the future of AI in healthcare, we want to hear from you. Apply today - https://lnkd.in/ebnH4Aha #Hiring #AIMedicalImaging #SaMD 

This Week’s Health & BioTech Funding Rounds 🚀 Health and BioTech investment is accelerating, driving advancements in precision medicine, AI diagnostics, and next-gen therapeutics. At KenkoTech Futures, we’re tracking the latest funding rounds shaping the future of healthcare. Here are this week’s key raises: AusperBio (Series B) $63M Until (Series A) $58M Salt AI (Seed) $10M Rapid Nexus Nanotech Wound Solutions, Inc. (Seed) $3.8M Caregility (Series C) $25.1M ArkeaBio™ (Series A) $7M VedaBio (Series A) $25M Sperity Health (Seed) $1.275M  Sparrow Pharmaceuticals, Inc. (Series B) $95M AmplifyMD (Series B) $20M Bonsai Health (Seed) $7M Daymark Health (Series A) $20M Axon Therapies Inc. (Series A) $32M Inspiren (Series B) $100M #KenkoTechFutures #HealthTech #BioTech #FundingRounds #Innovation #HealthcareTech #Startups

A recent study in the American Journal of Roentgenology (AJR) demonstrates the transformative power of AI in breast cancer screening. A commercial, FDA-cleared AI system was found to achieve a negative predictive value (NPV) on par with human radiologists, confirming its ability to reliably identify negative exams. 💡 This core finding highlights AI’s potential to act as a powerful ally for radiologists. By safely triaging a significant number of negative exams, AI can free up radiologists to focus their expertise on the most complex and challenging cases. The study also revealed that the AI system identified more potential risks than radiologists, serving as a valuable safety net to help ensure no sign of disease goes unnoticed. This research strongly positions AI not as a replacement, but as an essential tool for advancing breast cancer screening. While the study indicated that the higher recall rates associated with the AI system will require further refinement, this challenge presents an opportunity for the industry to evolve and integrate this powerful technology even more effectively into clinical practice. #AI #Radiology #KenkoTech